Skip to content

Chikungunya vaccination at the pharmacy

Which trips the Ständige Impfkommission recommends the chikungunya vaccination for, where the disease occurs, what is known about the protection it gives and who pays.

As of: 10/11/2026

Since 2 July 2026 trained pharmacists may vaccinate adults aged 18 and over against chikungunya. § 20c of the Infektionsschutzgesetz, the German infection protection act, lets them use only vaccines that are not live vaccines. Two vaccines against chikungunya are licensed in Germany, a live vaccine and an inactivated vaccine, and pharmacies use only the inactivated one. It contains virus-like particles that carry none of the virus’s genetic material and cannot multiply. The vaccination consists of one dose injected into the muscle. The pharmacies offering it are listed further down this page.

Which trips the vaccination is recommended for

The Ständige Impfkommission at the Robert Koch-Institut, Germany’s standing committee on vaccination, recommends it for adults visiting areas with a known current chikungunya outbreak. That is from its 2026 travel vaccination recommendations. It publishes them with the Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit (DTG), a German society for tropical and travel medicine. Without an outbreak, the committee recommends the vaccination when both of these apply:

  • You are planning a stay of more than four weeks, or repeated short stays, in an area where chikungunya is widespread.
  • You have a raised risk of severe or long-lasting illness, for example from the age of 60 or with a serious underlying medical condition.

The Robert Koch-Institut names chronic diseases of the kidneys, heart and lungs, and diabetes, as conditions that can raise the risk of severe illness. It says the data on this are inconsistent. According to the 2026 recommendations, only the inactivated vaccine should be used for people aged 60 and over.

In the rationale for its 2025 recommendation, the Ständige Impfkommission rates the general risk as low on trips to areas where chikungunya is widespread. According to the 2026 recommendations, the risk is highest on a trip to an area with a current outbreak. It rises with the length of the stay and is higher during and after the rainy season. For people visiting friends or relatives abroad, the recommendations cite studies that found a raised risk, including for chikungunya.

What chikungunya is

Chikungunya is a viral disease transmitted by mosquitoes of the genus Aedes. The 2026 recommendations name the yellow fever mosquito, which lives in tropical and subtropical regions, as the main carrier. The Asian tiger mosquito, which also occurs in Europe, can transmit the virus too. The mosquitoes bite mainly during the day, but also at night.

Most people who are infected develop symptoms. According to the recommendations, high fever, pain in several joints and a rash are typical. In the first phase of the illness, about 80 in 100 people who fall ill have pain in several joints. About 40 to 50 in 100 have a rash. For 40 to 80 in 100 of them, the joint pain lasts longer than three to six months.

In rare cases the illness is life-threatening, for example with inflammation of the brain or heart. There is no treatment against the virus itself, only for the symptoms.

Where chikungunya occurs

Mainly in tropical and subtropical regions. From 1999 to 2020, transmission was reported in 115 countries, according to the 2026 recommendations. These countries are in Africa, Asia, Oceania, North, Central and South America and Europe. For 2025 the recommendations cite World Health Organization figures of more than 500,000 recorded cases from more than 40 countries and territories. The number of people who fell ill is higher, the recommendations say, because diagnosis and surveillance are lacking.

For current outbreaks, the recommendations refer to the regularly updated country lists of the US health agency CDC and the European health agency ECDC.

For more than 140 countries and territories, the country tables to these recommendations list chikungunya under additional vaccinations where the trip brings a risk. These include Egypt, Brazil, the Dominican Republic, India, Kenya, Cuba, the Maldives, Mauritius, Mexico, Sri Lanka, Thailand and Tunisia. For Greece, Italy, Morocco, Spain and Türkiye the tables list no chikungunya vaccination. They say in their preface that they do not show current outbreaks.

Up to 2025, single locally acquired infections were recorded repeatedly in southern Europe, according to the Robert Koch-Institut. In Italy there were also larger outbreaks. Most cases in Europe are linked to travel, according to the institute. From 2016 to 2019, a median of 9 cases a year was reported in travellers returning to Germany. In 2023 there were 44 cases, and in 2024 there were 42.

How well the vaccination protects

There are no clinical data on how well the vaccination protects against illness, according to the 2026 recommendations. Instead, the studies counted how many vaccinated people produced enough antibodies against the virus. According to the Robert Koch-Institut, such values are regarded as an established sign of protection.

For vaccination with the inactivated vaccine, the 2025 rationale cites two studies. In the first, with people aged 12 to 64, 97.8% of those vaccinated had such antibodies 22 days after vaccination. In the comparison group, which received a placebo, the figure was 1.2%. After about six months it was 85.5% among the vaccinated people followed up, and the values fell with age.

The second study was in people aged 65 and over. After 22 days, 87.3% of those vaccinated and 1.1% of the comparison group had such antibodies. After about six months, 75.5% of the vaccinated people followed up still had them. The Ständige Impfkommission has some reservations about the six-month figures in both studies, because it could not fully reconstruct how the follow-up was done.

In the first study, 23.9% of those vaccinated reported pain, redness or swelling at the injection site in the first eight days. In the comparison group it was 10.7%. General reactions such as fever, tiredness, headache or joint pain occurred in 32.2% of those vaccinated and 24.9% of the comparison group. Joint pain alone was almost equally common in both groups, at 7.7% of those vaccinated and 7.2% of the comparison group.

How to protect yourself from mosquito bites

Alongside the vaccination, the 2026 recommendations name all-day protection against mosquitoes. As a rule, they say, it also protects against other infections for which there is no vaccination. The recommendations list:

  • sleeping under insecticide-treated, fine-mesh mosquito nets
  • staying in rooms with air conditioning or mosquito screens
  • wearing light-coloured clothing that covers the skin
  • using mosquito repellent all day
  • emptying open water containers in which mosquitoes breed

According to the recommendations, no case transmitted by a mosquito in Germany had been recorded up to and including 2025. Mosquitoes that can transmit the virus occur in some regions, however. In the first week of illness, people with chikungunya usually have the virus in their blood and so can help spread it. For that reason the recommendations name all-day protection against mosquitoes for up to 14 days after the trip, even without symptoms. This applies in the mosquito season in Germany, from summer to early autumn, above all in areas with the Asian tiger mosquito.

Who pays for the vaccination

For a private trip you have no statutory entitlement, but many insurers refund travel vaccinations voluntarily, according to the 2026 recommendations. Because insurers differ on this, travellers are told to ask theirs. For a work trip abroad, the recommendations say the vaccination can be refunded through the employer.

People with statutory insurance are entitled when the trip falls under the recommendation and the stay abroad is required by work or training. The rule is § 20i of the Fünftes Sozialgesetzbuch, the German statutory health insurance code. The Schutzimpfungs-Richtlinie is a directive of the Gemeinsamer Bundesausschuss, the body that decides what statutory insurers cover. It names the same trips for this as the Ständige Impfkommission. Apart from travel, it entitles insured people who, under the Biostoffverordnung, work specifically with chikungunya viruses, for example in a laboratory. The Biostoffverordnung is the German ordinance on biological agents at work.

Frequently asked questions

I have had chikungunya before. Do I need the vaccination?

The Ständige Impfkommission does not recommend the vaccination for people who have already had chikungunya. After an infection, lifelong immunity is presumed, according to the 2026 travel vaccination recommendations.

My trip starts in a few days. Can I still have the vaccination?

Yes, according to the Robert Koch-Institut, because the vaccination consists of one dose. With less than two weeks from vaccination to arrival in the area, the institute assumes protection is not yet complete when the trip starts. In that case protection against mosquitoes is especially important. The pharmacy will work out with you whether the vaccination is an option for you.

Will I need a booster later?

That cannot be said yet, according to the 2026 travel vaccination recommendations. The Robert Koch-Institut says the Ständige Impfkommission is following the data and intends to review its recommendation once new findings are available. According to the institute, first study results for both licensed vaccines show that the effect probably lasts several years.

Can I have another vaccination at the same appointment?

According to the Robert Koch-Institut, there are no studies yet on giving the chikungunya vaccination at the same time as other vaccinations. A vaccination with an inactivated vaccine needs no minimum gap to other vaccinations, according to the 2026 travel vaccination recommendations. Reactions to an earlier vaccination should have passed first, they say. Whether two can be given at one appointment depends on the Fachinformation of each vaccine, the product information for health professionals. The pharmacy will work this out with you.

I am pregnant or breastfeeding. Can I still have it?

For the inactivated vaccine there are only very few data on use during pregnancy and breastfeeding, according to the Ständige Impfkommission’s 2025 rationale. For that reason, benefit and risk should be weighed. In general, the rationale advises against travel during pregnancy and breastfeeding to an area where chikungunya is widespread. Other mosquito-borne diseases occur there that can be a risk, for example to the pregnancy or to the newborn. At the pharmacy or your doctor’s practice, talk through whether the vaccination is an option for you.

What if I have a weakened immune system?

According to the Robert Koch-Institut, the inactivated vaccine can also be used with a weakened immune system, after weighing benefit and risk. There are no data on efficacy and safety in people whose immune system is suppressed by whole-body treatment, according to the 2025 rationale. Because of the type of vaccine, it expects no higher safety risk. Depending on the treatment, the vaccination may work less well, it says. The rationale recommends vaccinating when the immune system is least suppressed. Talk through what that means for you at the pharmacy or at your doctor’s practice.

How long after infection do the first symptoms appear?

According to the 2026 travel vaccination recommendations, the first symptoms usually appear after 3 to 7 days. The range is 1 to 12 days. With a confirmed infection, the recommendations name all-day protection against mosquitoes in the season from summer to early autumn. This is to keep the virus from being passed on in Germany.

Coverage depends on your insurance and the reason for vaccination. Before your appointment, check with your insurer and the pharmacy whether vaccination there is covered or you must pay yourself.

Information as of 26/10/2026

Pharmacies vaccinating against Chikungunya

No listed pharmacy has reported this vaccination to us yet. That does not mean nobody offers it. Ask at your pharmacy.

Find a pharmacy near you

Enter an address or postcode to find nearby pharmacies with a recorded vaccination offer. Filter by vaccination if needed.

Sources

This page gives general information and names its sources. It does not replace medical or pharmaceutical advice. What is right in your case is something to settle at your pharmacy or doctor's practice.